- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
- Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.07 |
---|---|
High | 35.59 |
Low | 31.59 |
Bid | 34.62 |
Offer | 36.00 |
Previous close | 31.91 |
Average volume | 1.09m |
---|---|
Shares outstanding | 38.88m |
Free float | 33.24m |
P/E (TTM) | -- |
Market cap | 1.24bn USD |
EPS (TTM) | -2.25 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼